Cancidas Related Published Studies
Well-designed clinical trials related to Cancidas (Caspofungin)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. [2007.10.01]
Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. [2006.03]
Potential for interactions between caspofungin and nelfinavir or rifampin. [2004.11]
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. [2004.09.30]
Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. [2003.08]
Comparison of caspofungin and amphotericin B for invasive candidiasis. [2002.12.19]
Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. [2002.09.01]
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. [2002.09]
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. [2002.03]
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. [2002.02]
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. [2001.11.01]
Well-designed clinical trials possibly related to Cancidas (Caspofungin)
Double-blind active-control trials: beware the comparator you keep. [2008.10.15]
Invasive candidiasis in cancer patients: observations from a randomized clinical trial. [2005.06]
Other research related to Cancidas (Caspofungin)
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. [2008.08.01]
Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. [2008.08]
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. [2008.08]
Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. [2008.07.15]
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. [2008.07]
Combination Polyene-Caspofungin Treatment of Rhino-Orbital-Cerebral Mucormycosis. [2008.06.17]
Caspofungin disk diffusion breakpoints and quality control. [2008.06]
Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy. [2008.05.20]
Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin. [2008.05.15]
Successful treatment of disseminated Geotrichum capitatum infection with a combination of caspofungin and voriconazole in an immunocompromised patient. [2008.05]
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. [2008.05]
Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. [2008.05]
Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. [2008.04]
Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. [2008.04]
Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. [2008.03.07]
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery. [2008.03.01]
Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. [2008.03]
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. [2008.02]
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. [2008.02]
Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. [2008.01]
Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole. [2008.01]
Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. [2008]
Experiences with the use of caspofungin in paediatric patients. [2008]
Caspofungin for treatment of invasive aspergillus infections. [2008]
Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy. [2008]
Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. [2008]
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). [2007.12.15]
Efficacy and safety of caspofungin in solid organ transplant recipients. [2007.12]
Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. [2007.12]
Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. [2007.12]
Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model. [2007.12]
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (combistrat trial). [2007.10.16]
Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. [2007.10.11]
Disseminated invasive aspergillosis with cerebral involvement successfully treated with caspofungin and voriconazole. [2007.10]
Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. [2007.09.27]
Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. [2007.09]
Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. [2007.08]
Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. [2007.08]
Caspofungin for the treatment of less common forms of invasive candidiasis. [2007.08]
Efficacy of topical caspofungin in experimental fusarium keratitis. [2007.07]
Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. [2007.07]
A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. [2007.06]
The use of caspofungin in HIV-infected individuals. [2007.06]
Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. [2007.06]
A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland. [2007.06]
Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. [2007.04.18]
A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. [2007.04.05]
The pharmacology and clinical use of caspofungin. [2007.04]
Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. [2007.03.15]
Caspofungin in the treatment of symptomatic candiduria. [2007.03.01]
Caspofungin in combination with amphotericin B against Candida parapsilosis. [2007.03]
Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. [2007.02]
Caspofungin for the treatment of azole resistant candidemia in a premature infant. [2007.02]
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. [2007.02]
Invasive esophageal aspergillosis associated with acute myelogenous leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. [2007.01]
The effects of caspofungin and voriconazole in experimental Candida endophthalmitis. [2007.01]
Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. [2007]
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. [2006.12.15]
Efficacy and safety of caspofungin therapy in children with invasive fungal infections. [2006.12]
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. [2006.12]
Caspofungin: a major breakthrough in treatment of systemic fungal infections. [2006.12]
Development of candidemia on caspofungin therapy: a case report. [2006.12]
Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. [2006.12]
Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin. [2006.11]
Caspofungin for invasive candidiasis at a tertiary care medical center. [2006.11]
An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. [2006.10]
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. [2006.10]
Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. [2006.09.01]
Clinical efficacy of caspofungin in the treatment of invasive aspergillosis. [2006.09]
Limitations of caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection. [2006.08.08]
Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. [2006.08.01]
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. [2006.08]
Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. [2006.08]
Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. [2006.07]
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. [2006.07]
Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature. [2006.07]
A case of pulmonary aspergillosis with lack of response to caspofungin. [2006.06]
Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. [2006.06]
Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. [2006.05]
Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. [2006.05]
Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. [2006.04.11]
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. [2006.04]
Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. [2006.04]
Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. [2006.03]
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. [2006.02.15]
Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole. [2006.02.15]
Caspofungin in the treatment of invasive fungal infections. [2006.02]
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. [2006.01.15]
|
